The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of COIN, CRMD and HNST - Yahoo Finance
NEW YORK, NY / ACCESSWIRE / September 20, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Coinbase Global, Inc. (NASDAQ:COIN)
This lawsuit is on behalf of all persons and entities that purchased or otherwise acquired Coinbase Class A common stock pursuant and/or traceable to the Company's registration statement and prospectus for the resale of up to 114,850,769 shares of its Class A common stock, whereby Coinbase began trading as a public company on or around April 14, 2021.
Lead Plaintiff Deadline: September 20, 2021
The COIN lawsuit alleges that Coinbase Global, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company required a sizeable cash injection; (2) the Company's platform was susceptible to service-level disruptions, which were increasingly likely to occur as the Company scaled its services to a larger user base; and (3) as a result of the foregoing Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in COIN: https://www.kleinstocklaw.com/pslra-1/coinbase-global-inc-loss-submission-form?id=19707&from=1
CorMedix Inc. (NASDAQ:CRMD)
Class Period: October 16, 2019 - May 13, 2021
Lead Plaintiff Deadline: September 20, 2021
The complaint alleges that during the class period CorMedix Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) deficiencies existed with respect to an investigational drug product, DefenCath's, manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) in light of the foregoing deficiencies, the Food and Drug Administration was unlikely to approve the DefenCath new drug application for catheter-related bloodstream infections in its present form; (iii) Defendants had downplayed the true scope of the deficiencies with DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
source: https://finance.yahoo.com/news/klein-law-firm-reminds-investors-141000159.html
Your content is great. However, if any of the content contained herein violates any rights of yours, including those of copyright, please contact us immediately by e-mail at media[@]kissrpr.com.